|
|
|
10061
|
|
|
P.I.:
|
Joanne Mortimer, MD
|
(Industrial)
|
|
Title:
|
Biomarker Evaluation and Selection of Targeted Therapy (BEST-Rx)
|
|
|
10055
|
|
|
P.I.:
|
Paul Lin, MD
|
(Cooperative Group)
|
|
Title:
|
GOG 0240: A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab (NSC #704865, IND #7921) Versus the Nonplatinum Doublet, Topotecan Plus Paclitaxel, with and without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix
|
| | |
|
|
10051
|
|
|
P.I.:
|
Nayana Vora, MD
|
(Cooperative Group)
|
|
Title:
|
RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
|
| | |
|
|
10040
|
|
|
P.I.:
|
Warren Chow, MD
|
(Industrial)
|
|
Title:
|
The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna versus decarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation
|
| | |
|
|
10035
|
|
|
P.I.:
|
Vijay Trisal, MD
|
(Industrial)
|
|
Title:
|
An Exploratory Analysis of Tumor Specific T Cells in Subjects with Clinically and Histologically Diagnosed Cancer
|
|